{
  "trial_id": "NCT00328172",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, BMI (Body Mass Index), duration of Type 2 diabetes, baseline HbA1c, baseline fasting plasma glucose, prior antidiabetic therapy, renal function (serum creatinine), hepatic function (serum levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase), history of cardiovascular disease, history of central nervous system or psychiatric disorders, history of chronic or acute infections, history of allergy/hypersensitivity, alcohol or drug use history, reproductive status (for pre-menopausal women).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Body Mass Index (BMI)",
          "BMI (Body Mass Index)"
        ],
        [
          "Baseline glycosylated hemoglobin (HbA1c)",
          "baseline HbA1c"
        ],
        [
          "Fasting blood plasma glucose (FPG)",
          "baseline fasting plasma glucose"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race/Ethnicity"
      ],
      "remaining_candidate_features": [
        "duration of Type 2 diabetes",
        "prior antidiabetic therapy",
        "renal function (serum creatinine)",
        "hepatic function (serum levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase)",
        "history of cardiovascular disease",
        "history of central nervous system or psychiatric disorders",
        "history of chronic or acute infections",
        "history of allergy/hypersensitivity",
        "alcohol or drug use history",
        "reproductive status (for pre-menopausal women)"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Baseline HbA1c, Body Mass Index, Duration of Diabetes, Fasting Plasma Glucose, Use of Oral Hypoglycemic Agents,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Body Mass Index (BMI)",
          "Body Mass Index"
        ],
        [
          "Baseline glycosylated hemoglobin (HbA1c)",
          "Baseline HbA1c"
        ],
        [
          "Fasting blood plasma glucose (FPG)",
          "Fasting Plasma Glucose"
        ]
      ],
      "remaining_reference_features": [],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Duration of Diabetes",
        "Use of Oral Hypoglycemic Agents"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Diabetes Diagnosis Duration, Body Mass Index, HbA1c, Fasting Plasma Glucose, Systolic Blood Pressure, Diastolic Blood Pressure, History of Cardiovascular Disease, Antidiabetic Therapy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Body Mass Index (BMI)",
          "Body Mass Index"
        ],
        [
          "Baseline glycosylated hemoglobin (HbA1c)",
          "HbA1c"
        ],
        [
          "Fasting blood plasma glucose (FPG)",
          "Fasting Plasma Glucose"
        ]
      ],
      "remaining_reference_features": [],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Diabetes Diagnosis Duration",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "History of Cardiovascular Disease",
        "Antidiabetic Therapy"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, BMI, duration of Type 2 diabetes, HbA1c at screening, fasting plasma glucose, systolic and diastolic blood pressure, heart rate, medical history (including cardiovascular disease, hepatic or renal insufficiency, neurologic disorders, infections), concomitant medications, smoking status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Body Mass Index (BMI)",
          "BMI"
        ],
        [
          "Baseline glycosylated hemoglobin (HbA1c)",
          "HbA1c at screening"
        ],
        [
          "Fasting blood plasma glucose (FPG)",
          "fasting plasma glucose"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race/Ethnicity"
      ],
      "remaining_candidate_features": [
        "duration of Type 2 diabetes",
        "systolic and diastolic blood pressure",
        "heart rate",
        "medical history (including cardiovascular disease, hepatic or renal insufficiency, neurologic disorders, infections)",
        "concomitant medications",
        "smoking status."
      ]
    }
  }
}